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Vitamin D and susceptibility to 
infectious diseases: no cure  
for the common cold
ABSTRACT
Vitamin D influences innate immunity through up-regulation of antimicrobial peptides and adaptive immunity 
through modulation of both T-lymphocyte and B-lymphocyte function. Several observational studies have 
shown an association between low serum 25(OH)D levels and the incidence and severity of respiratory 
infections and also tuberculosis. Such studies, however do not fully account for confounding variables or 
reverse causality. The recent emergence of higher quality randomised controlled trials, however has so far 
not established a role for routine vitamin D supplementation in the general population for the prevention 
of respiratory infections. Further research, however may identify sub-groups to whom this intervention 
might be more appropriately targeted. 
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Introduction
Vitamin D is traditionally associated with bone 
health, although has been increasingly implicated in 
many other disease processes, including susceptibility 
to infectious diseases. There are plausible mechanisms 
through which vitamin D modulates immune function, 
including actions on both the innate and adaptive 
components [1]. The innate immune system is the first 
line of defence, which includes all mechanisms that 
prevent invasion without the need for memory from 
previous pathogen exposure. The main components 
of innate immunity include physical barriers (e.g. skin, 
tears, mucous, saliva) and non-specific inflammatory 
responses of tissues. The innate system prevents 
infection without any requirement for immunological 
memory from previous exposure to the pathogen [2]. 
Innate immunity includes the production of antimi-
crobial peptides, capable of killing viruses, bacteria and 
other organisms [3, 4]. These peptides are produced 
on epithelial surfaces and within circulating white blood 
cells. Examples include human b-defensins 2 and 3 and 
cathelicidin (also known as hCAP-18 and LL-37) [4]. 
The peptides are produced through the effect of Toll 
like receptors, on the surface of macrophages and 
monocytes, causing cell activation when they recog-
nize molecules derived from pathogens [4, 5]. This 
activation results in expression of the genes that code 
for the vitamin D receptor, and for the 1a-hydroxylase 
enzyme that converts the pre-hormone, 25(OH)D, to 
the biologically active 1,25 dihydroxyvitamin D; which 
in turn activates the gene that produces cathelicidin [5]. 
Cathelicidin has both direct (increased membrane per-
meability) and indirect effects (chemotaxis of immune 
cells) which neutralise the pathogen. An increase in the 
concentration of cathelicidin in phagocytic vacuoles 
enhances the cells ability to kill micro-organisms [4]. 
LL-37, the only human cathelicidin, has been identified 
in white cells, breast milk, skin, lung, saliva, and colon. 
It is active against a wide range of microbes, including 
bacteria (both gram positive and gram negative), fungi 
and viruses [6]. 
The adaptive immune system is more complex 
than the innate system and is dependent upon the 
innate system for antigen presentation to which it then 
mounts a specific, remembered response [1]. The rela-
tionship of vitamin D with the adaptive immune system 
is similarly more complex. Vitamin D modulates both 
T-lymphocyte and B-lymphocyte function. Vitamin D 
suppresses T-helper cell proliferation and modulates 
their cytokine production. Cell mediated immunity is 
promoted and vitamin D has also been shown to have 
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a direct effect on B lymphocyte proliferation and immu-
noglobulin production [1]. 
Vitamin D and tuberculosis
The postulated mechanisms linking vitamin D and 
cathelicidin provide a possible explanation for the link 
between sun exposure, vitamin D and tuberculosis 
(TB) [7]. There is increasing evidence that low body 
vitamin D levels may increase the risk of developing 
TB. For example, a hospital-based case-control study 
found that vitamin D deficiency was associated with 
an odds ratio of 2.9 (95% CI 1.3–6.5) for having active 
TB [8]. A case series of London TB patients showed 
that 56% had undetectable plasma 25(OH)D levels 
(< 2.8 ng/mL) [9]. Another case-control study from West 
Africa observed lower mean serum 25(OH)D levels in 
cases (31 ng/mL) compared with controls (34 ng/mL); 
p < 0.001) [10]. Susceptibility to TB has been linked to 
vitamin D-receptor polymorphisms, with the presence 
of the FokI F allele protecting against TB infection, and 
the TaqI t allele protecting against active disease but 
not infection [11]. 
Vitamin D and respiratory infection
The association between rickets and infection has 
been known for several decades [12]. Many studies 
have reported that children with rickets commonly 
present to hospital with respiratory infections [13–21]. 
One of these observed lower serum 25(OH)D levels in 
cases of acute severe lower respiratory infection requir-
ing admission to hospital compared with controls: 9.2 v. 
15.2 ng/mL (p < 0.0001) [21]. 
Exposure to sunshine and UVB, which is the primary 
source of vitamin D in humans, is also associated with 
respiratory infection markers [22]. Sub-erythemal cours-
es of UV radiation, administered twice a year for three 
years to Russian teenage athletes, resulted in fewer 
respiratory viral infections, fewer days of absences and 
shorter duration of illness, compared with non-irradiated 
athletes [23]. 
A study from the Netherlands found that children 
with low sun exposure were more likely to have a cough 
and a runny nose, compared to children with highest 
sun-exposure [24]. The temporal association between 
seasonal changes in vitamin D levels and winter re-
spiratory virus activity has led to the proposal that low 
vitamin D levels may have a causal role in the onset of 
influenza epidemics [25, 26].
Several observational studies have reported on vi-
tamin D status and respiratory infection. A case-control 
study from Turkey found that serum 25(OH)D levels 
were lower in neonatal cases of acute lower respira-
tory infection (9.2 ng/mL) than age-matched controls 
(16.4 ng/mL) [27]. A cohort study from Finland found 
that young male soldiers with serum 25(OH)D lev-
els < 16 ng/mL at baseline had a 63% increased risk 
of absence from duty over the following 6 months due 
to respiratory infection compared with soldiers with 
levels > 16 ng/mL (p = 0.004) [28]. A case-control 
study of children aged 1-25 months found no differ-
ence in mean serum 25(OH)D levels between cases of 
acute lower respiratory tract infection (30.8 ng/mL) and 
hospital controls (30.8 ng/mL) [29]. This observation, 
however is probably due to virtually all of the infants 
having high vitamin D diets through fortified formula or 
supplementation. Further analysis of the US NHANES 
III survey showed that, after adjusting for demographic 
and clinical characteristics, lower 25(OH)D levels were 
independently associated with self-reported URI in 
the past few days (compared to ≥ 30 ng/mL group: 
OR 1.36 [95% CI 1.01–1.84] for < 10 ng/mL and OR 
1.24 [95% CI 1.07–1.43] for 25–74 nmol/L groups) [30]. 
Observational studies of vitamin D and respiratory 
infection, however are likely to be affected by confound-
ing variables that are not fully accounted for. They are 
also likely to be affected by the phenomenon of reverse 
causality, where subjects who are ‘sickly’ for whatever 
reason are less likely to spend time outdoors exposed to 
sunlight. In accordance with the principles of Evidence 
Based Medicine, strong evidence of whether there is 
a true effect of vitamin D on the risk of infection can really 
only be provided by randomised controlled trials (RCTs) 
of intervention. This point was reinforced in a system-
atic review, published in 2009 by Yamschikov et al., 
who identified 13 clinical trials addressing the effect 
of vitamin D on treatment and prevention of infectious 
diseases in humans [31]. Considerable heterogeneity 
existed amongst the individual studies reviewed and it 
was concluded that more rigorously designed clinical 
trials were needed in this area.
Vitamin D supplementation  
and respiratory infection
Recent randomised controlled trials (RCTs) of vita-
min D supplementation have examined its impact on 
respiratory infection. A study designed to investigate 
bone-loss in post-menopausal African-American women 
found that 8% of women on 800 to 2000 IU per day 
reported having cold or influenza symptoms over the 
3 years follow-up compared with 25% of women on pla-
cebo (p < 0.002) [32]. The prevalence of URI symptoms 
in this study, however will have been underestimated 
due to the insensitive and imprecise manner in which 
these data were collected, although the double-blinded, 
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randomised study design should have minimised 
reporting bias. In a sub-study of an RCT to prevent 
fractures with vitamin D supplementation, 3444 par-
ticipants (mean age 77 years) were asked in winter if 
they had suffered an infection or received antibiotics 
during the previous week [33]. For intention-to-treat 
comparisons, there was a non-significant 10% reduc-
tion in the odds of reporting infection (p = 0.23) and 
16% reduction in the odds of reporting antibiotic use 
(p = 0.18). Slightly stronger effects were observed for 
on-treatment per-protocol comparisons: 20% reduction 
in reporting infection (p = 0.06) and 26% reduction in 
reporting antibiotics (p = 0.10). The limitations of this 
study include the short outcome period of only one 
week, which reduced power, and its low dose of vitamin 
D (800 IU/day) which increased 25(OH)D levels from 
15.2 ng/mL to only 24.8 ng/mL, well below the 32 to 
40 ng/mL range now considered to be associated with 
optimum adult health outcomes [34–37]. 
More recently, our group reported a randomized, 
placebo-controlled double blind clinical trial to de-
termine the effect of vitamin D supplementation on 
incidence and severity of upper respiratory infections 
(URIs) in healthy adults [38]. In the Vitamin D and re-
spiratory infection study (VIDARIS), 322 healthy adults 
(161 in each treatment group) were enrolled, who 
were employees of our local hospital board or univer-
sity, between February 2010 and November 2011 in 
Christchurch, New Zealand [38]. They were allocated 
to monthly oral 100,000 IU vitamin D3 after a loading 
dose or placebo for a total of 18 months. The primary 
end point was number of URI episodes. Secondary end 
points were duration of URI episodes, severity of URI 
episodes, number of days off work as a result of URI 
episodes, and detection of respiratory viruses in naso-
pharyngeal samples. The mean baseline 25(OH)D level 
was 29 (SD 9) ng/mL, and only five (1.6%) participants 
had levels < 10 ng/mL. Vitamin D supplementation re-
sulted in an increase in serum 25(OH)D levels that was 
maintained at > 48 ng/mL throughout the study [38]. 
There were 593 URI episodes in the vitamin D group 
and 611 in the placebo group, with no statistically signif-
icant differences in the number of URIs per participant 
[mean 3.7 per person for the vitamin D group, 3.8 for 
the placebo group; RR 0.97 (95% CI 0.85–1.11)]. There 
were also no significant differences in the number of 
days off work as a result of URIs [0.76 for each group; 
RR 1.03 (95% CI 0.81–1.30)], duration of symptoms per 
episode [mean 12 days for each group; RR 0.96 (95% 
CI 0.73–1.25)] or severity of URI episodes [38]. These 
findings remained unchanged when the analysis in-
cluded season or baseline 25(OH)D levels. We also 
documented no episodes of hypercalcemia nor any 
adverse events attributed to vitamin D. The monthly 
administration of 100,000 IU vitamin D3 was therefore 
not found to reduce the incidence or severity of URIs 
in healthy, predominantly European adults with near 
normal vitamin D levels [38]. 
The strengths of the VIDARIS study include the rela-
tively large sample size, the 18-month duration (includ-
ing two winters), and the high-dose of vitamin D3 ad-
ministered together with a loading dose, thus avoiding 
the shortcomings of previous adult studies. The dosing 
regimen, started during summer/autumn, resulted in 
sustained mean 25(OH)D levels > 48 ng/mL throughout 
the study period in those in the intervention arm. Other 
strengths are the stringent efforts to capture URI epi-
sodes and the collection of virological data. In VIDARIS, 
however we were unable to assess the effect of vitamin 
D supplementation on prevention of infection caused 
by individual viruses, although there were few cases of 
confirmed influenza among the group of partly-vacci-
nated participants [38].
The findings of the VIDARIS study are consistent with 
some but not all RCTs that were specifically designed 
to assess whether vitamin D supplementation prevents 
acute respiratory infections in adults. 
In a study of 162 adults, there was no benefit of 
vitamin D supplementation in decreasing the incidence 
or severity of URIs during winter [39]. This study, how-
ever was of short duration (12 weeks), underpowered, 
used a relatively low dose of vitamin D (2,000 IU daily) 
without a loading dose and first administered vitamin 
D3 during (rather than before) winter [39]. 
Laaksi et al. also showed no difference in the 
number of days absent from duty due to respiratory 
tract infection in 164 soldiers randomized to vitamin 
D3 (400 IU daily) or placebo for 6 months over winter, 
although the overall proportion of participants who had 
no days absent from duty was lower in the vitamin D 
group [40]. This study was also underpowered and the 
relatively low dose of vitamin D3 resulted in only 29% 
of those in the intervention group obtaining 25(OH)D 
levels > 32 ng/mL [40]. 
More recently, two studies showed differing effects 
of vitamin D supplementation in children. In a study 
conducted in Mongolia, classrooms of 744 Mongolian 
schoolchildren were randomly assigned to different 
treatments in winter and analysis focused on a subset 
of 247 children who were assigned to daily ingestion of 
unfortified regular milk (control, n = 104) or milk fortified 
with 300 IU vitamin D3 (n = 143); in double-blinded 
fashion [41]. At baseline, the median serum 25(OH)D 
level was 7.0 ng/mL (interquartile range, 5 to 10 ng/mL) 
[41]. At the end of the study period, the median 25(OH)D 
levels of children in the control versus vitamin D groups 
significantly differed (7.0 v. 19 ng/mL), respectively; 
p < 0.001) [41]. Compared to controls, children on 
vitamin D reported significantly fewer ARIs during the 
study period (mean: 0.80 v. 0.45 infections, respec-
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tively; p = 0.047), with a rate ratio [RR] of 0.52 (95% CI 
0.31–0.89) [41]. Adjusting for age, sex, and history of 
wheezing, vitamin D continued to halve the risk of ARI 
(RR 0.50, 95% CI 77 0.28–0.88) [41]. Similar results were 
found among children either below or above the median 
25(OH)D level at baseline (RR 0.41 v. 0.57, respectively; 
Pinteraction = 0.27) [41].
In contrast, vitamin D supplementation did not affect 
the incidence of first episodes of pneumonia in 1524 in-
fants from Afghanistan, another population with a high 
prevalence of vitamin D deficiency [42].
In a double-blind RCT for the prevention of acute 
respiratory infection in older adults and their carers (Vi-
DiFlu), the addition of intermittent bolus-dose vitamin D3 
supplementation to a daily low-dose regimen did not 
influence risk of acute respiratory infection in older 
adults and their carers [43].
In another RCT from New Zealand, healthy pregnant 
women, from 27 weeks’ gestation to birth, and their 
infants, from birth to age 6 months, were assigned to 
placebo or one of the two dosages of daily oral vita- 
min D3 [44]. In comparison with the placebo group 
(99%), the proportion of children making any acute re-
spiratory infection visits was smaller in the higher-dose 
(87%, p = 0.004), but not the lower-dose vitamin D3 
group (95%, p = 0.17) [44]. It was concluded that 
vitamin D3 supplementation during pregnancy and 
infancy reduces primary care visits for acute respiratory 
infection during early childhood [44].
In a 2X2 factorial, RCT to assess whether vitamin 
D3 supplementation (10,000 IU per week) versus pla-
cebo and gargling versus no gargling could prevent 
viral, clinical upper respiratory tract infection (URTI) 
in university students, 600 students were randomised 
into 4 treatment arms: 1) vitamin D3 and gargling, 
2) placebo and gargling, 3) vitamin D3 and no gar-
gling, and 4) placebo and no gargling [45]. Seventy 
participants (23.3%) randomized to vitamin D3 reported 
clinical URTI compared to 80 (26.7%) randomized to 
placebo (RR 0.79, 95% CI 0.61–1.03, p = 0.09). Vitamin 
D3 treatment was associated with a significantly lower 
risk for laboratory confirmed URTI (p = 0.007) and with 
a significantly lower mean viral load. It was concluded 
that vitamin D3 is a promising intervention for the pre-
vention of URTI [45]. 
In a post hoc analysis of data from pilot D-Health, 
an RCT in a general community setting, 644 Australian 
residents aged 60–84 y were randomly assigned to 
receive monthly doses of either placebo (n = 214) or 
30,000 (n = 215) or 60,000 (n = 215) IU oral cholecal-
ciferol [46]. Those participants assigned to 60,000 IU 
cholecalciferol, had 28% lower risk of having antibiotics 
prescribed at least once than did people in the placebo 
group (RR 0.72; 95% CI 0.48–1.07, although this was 
not significant [46]. 
In a RCT, 180 pregnant women were randomised 
at 27 weeks gestation to either no vitamin D, 800 IU 
ergocalciferol daily until delivery or single oral bolus 
of 200,000 IU cholecalciferol [47]. No difference was 
found between supplemented and control groups in 
risk of wheeze in the offspring and there was also no 
significant difference in atopy, eczema risk or lung 
function between the groups [47].
As an adjunct to a multi-centre, RCT of colorectal 
adenoma chemoprevention, it was tested whether 
1000 IU/day vitamin D(3) supplementation reduced 
winter episodes and duration of URTI and its composite 
syndromes [48]. The RCT included 2259 participants 
aged 45–75 and in otherwise good health, apart 
from history of colorectal adenoma, who were were 
randomized to vitamin D(3) (1000 IU/day), calcium 
(1200 mg/day), both, or placebo [48]. Participants had 
a baseline serum 25(OH)D level ≥ 12 ng/mL. It was 
found that supplementation did not significantly reduce 
winter episodes of URTI (RR 0.93, 95% CI 0.79–1.09) 
including colds [48].
The effect of adjunctive vitamin D for treatment of 
active tuberculosis was investigated in India in an RCT 
[49]. Of the 247 participants, 121 were assigned to vita-
min D intervention (four doses of 2·5 mg at weeks 0, 2, 
4, and 6) and 126 to the placebo group. Median time to 
sputum culture conversion in the vitamin D group was 
43·0 days (95% CI 33·3–52·8) v. 42·0 days (33·9–50·1) in 
the placebo group. Vitamin D supplementation therefore 
did not reduce time to sputum culture conversion [49]. 
Other significant trials are in progress and expect to 
report at a later date. For example, in North America, the 
DO IT Trial is a pragmatic RCT of vitamin D Outcomes 
and Interventions in Toddlers [50]. It is planned to recruit 
750 healthy children 1–5 years of age over 4 successive 
winters who will be randomized to either ‘standard 
dose’ or ‘high dose’ oral supplemental vitamin D for 
a minimum of 4 months. The aim is to identify whether 
vitamin D supplementation can reduce wintertime viral 
URTIs and asthma exacerbations [50].
In a recent trial of vitamin D supplementation to 
reduce exacerbations of chronic obstructive pulmo-
nary disease, vitamin D supplementation significantly 
reduced exacerbations only in patients with baseline 
25(OH)D levels < 10 ng/mL [51]. 
In a randomized controlled trial in Japanese school 
children, set up to assess the effect of vitamin D supple-
mentation on “doctor diagnosed influenza,” there was 
a statistically significant reduction in laboratory-con-
firmed influenza A infection (RR 0.58, p = 0.04) [52]. 
The findings of the various RCTs undertaken in this 
context are therefore mixed, although the VIDARIS study 
stands out for its methodological rigour, as indicated 
above [38]. A valid discussion point is whether the 
VIDARIS results would have been different if participants 
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had been given vitamin D 3,300 IU daily, as compared 
to 100,000 IU monthly. Different outcomes have been 
documented for trials of 4-monthly versus annual 
dosing regimens of vitamin D supplementation for risk 
of fractures [53, 54]. Several mechanisms have been 
proposed to explain how various dosing regimens may 
have different effects on immune function [55]. How-
ever, it is purely speculative at this stage as to whether 
some conditions (e.g. infections) require a smaller 
steady dose of vitamin D supplementation for benefit. 
Another plausible hypothesis is that genetic variation 
in vitamin D metabolism or signalling may modify the 
anti-infective effects of vitamin D. Vitamin D receptor 
polymorphisms, for example have been linked to both 
susceptibility to tuberculosis [56] and the response to vi-
tamin D supplements in patients with tuberculosis [57].
Conclusions
Vitamin D may influence immune function through 
actions on both the innate and adaptive systems. Ob-
servational studies have shown an association between 
low 25(OH)D levels and the incidence and severity of 
respiratory infections, although do not fully account for 
confounding variables or reverse causality. The emer-
gence of higher quality randomised controlled trials, 
such as the New Zealand based VIDARIS study, how-
ever has so far not conclusively established a role for 
routine vitamin D supplementation in otherwise healthy 
adults for prevention of respiratory infections. Further 
intervention studies, however should focus on other 
sub-groups, including children with lower baseline 
vitamin D levels.
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